Mapracorat (INN, code names BOL-303242-X, ZK-245186[1]) is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs).

It is in clinical trials for the topical treatment of atopic dermatitis,[2] inflammation following cataract surgery,[3] and allergic conjunctivitis.

This trial was conducted by Intendis, a part of Bayer HealthCare Pharmaceuticals specialized on dermatology, and completed in September or October 2010.

[2] The other trial, also with a double blind design, evaluated an ophthalmic suspension for the treatment of inflammation following cataract surgery.

[3] Its successor study, a phase III trial, started in November 2010 and completed in August 2011.